Autonomix Medical Files 8-K on Agreements and Equity Sales

TL;DR

Autonomix Medical (AMIX) filed an 8-K detailing new agreements and equity sales.

AI Summary

Autonomix Medical, Inc. filed an 8-K on November 19, 2025, reporting on events that occurred on November 18, 2025. The filing indicates the company entered into a material definitive agreement and also addresses unregistered sales of equity securities. Financial statements and exhibits are included as part of the report.

Why It Matters

This 8-K filing signals significant corporate actions by Autonomix Medical, Inc., potentially impacting its financial structure and operational agreements.

Risk Assessment

Risk Level: medium — The filing mentions unregistered sales of equity securities, which can sometimes indicate dilution or less favorable terms for existing shareholders.

Key Players & Entities

• Autonomix Medical, Inc. (company) — Registrant
• November 18, 2025 (date) — Date of earliest event reported
• November 19, 2025 (date) — Filing date
• 21 Waterway Avenue, Suite 300 (address) — Principal executive offices
• The Woodlands, TX 77380 (address) — Principal executive offices
• ( 713 ) 588-6150 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — h Registered Common Stock , par value $0.001 per share AMIX The Nasdaq Stock Mark
• $1.1097 — nt and accompanying Common Warrants was $1.1097. Subject to certain ownership limitati
• $0.8607 — of Common Stock at a price per share of $0.8607 (as adjusted from time to time in accor
• $5.0 m — ny from the Offering were approximately $5.0 million, before deducting the Placement A
• $1.1107 — ock in such transaction is greater than $1.1107 per share. The Pre-Funded Warrants and
• $50,000 — reimburse the Placement Agent for up to $50,000 for the Placement Agent's fees and expe

Filing Documents

• amix20251118c_8k.htm (8-K) — 36KB
• ex_890598.htm (EX-1.1) — 63KB
• ex_890599.htm (EX-4.1) — 95KB
• ex_890600.htm (EX-4.2) — 98KB
• ex_890601.htm (EX-10.1) — 242KB
• logo.jpg (GRAPHIC) — 2KB
• 0001437749-25-035733.txt ( ) — 801KB
• amix-20251118.xsd (EX-101.SCH) — 3KB
• amix-20251118_def.xml (EX-101.DEF) — 12KB
• amix-20251118_lab.xml (EX-101.LAB) — 16KB
• amix-20251118_pre.xml (EX-101.PRE) — 12KB
• amix20251118c_8k_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On November 18, 2025, Autonomix Medical, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Agreement") with an institutional investor (the "Investor"), pursuant to which the Investor purchased in a private placement: (i) pre-funded warrants to purchase 4,501,666 shares of the Company's common stock, $0.001 par value per share ("Common Stock") (the "Pre-Funded Warrants"); and (ii) Series C Warrants to purchase up to an aggregate of 9,003,332 shares of Common Stock (the "Common Warrants") (the "Offering"). The Common Warrants and Pre-Funded Warrants are collectively referred to herein as the "Warrants". The combined purchase price of one Pre-Funded Warrant and accompanying Common Warrants was $1.1097. The Common Warrants may be exercised on a cashless basis if, at any time after the six-month anniversary of the Initial Exercise Date, there is no registration statement registering, or the prospectus contained therein is not available for, the issuance or resale of shares of Common Stock underlying the Common Warrants to or by the holder. The holder of a Common Warrant is prohibited from exercising any Common Warrants to the extent that such exercise would result in the number of shares of Common Stock beneficially owned by such holder and its affiliates exceeding 4.99% of the total number of shares of Common

02. Unregistered Sales of Equity Securities

Item 3.02. Unregistered Sales of Equity Securities. The information set forth in Item 1.01 relating to the Common Stock and Warrants issued in the Offering and the shares issuable upon exercise of the Warrants is incorporated by reference herein.

01. Exhibits

Item 9.01. Exhibits. (d) Exhibits Exhibit No. Description 1.1 Placement Agency Agreement, dated November 18, 2025, with Maxim Group LLC 4.1 Form of Pre-Funded Warrant 4.2 Form of Series C Warrant 10.1 Form of Securities Purchase Agreement, dated November 18, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTONOMIX MEDICAL, INC. By: /s/ Trent Smith Trent Smith Chief Financial Officer Dated: November 19, 2025

View Full Filing

View this 8-K filing on SEC EDGAR